BBIO · NASDAQ · STOCK
BridgeBio Pharma (BBIO) Stock Analysis
$74.86
52W $48.78 – $93.42
49/100
$14.66B
-20.9
0.97
Is BBIO Bullish or Bearish?
Mixed.
Innellis AI committee rates BridgeBio Pharma, Inc. (BBIO) Watch with a composite score of 49/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +10.77 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -9.23 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — price-to-book of 150.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 202.4% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.27 across 25 articles, 14d) — News
Bear Case
- Price-to-book of 150.7x prices in significant intangible value — Value
- ROE of only -206.7% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 8.27 adds balance-sheet risk to the value case — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 17 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
49/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 99%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 150.7x prices in significant intangible value
Growth Analyst
neutral
47
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Revenue growing 202.4% YoY -- genuine top-line momentum
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 17 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 8.27) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 25 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 49.2 to 49.2.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
17.5
Oversold
MACD Histogram
-0.787
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$62.84
Resistance
$83.29
Bollinger %B
0.09
Inside Bands
Price vs Moving Averages
EMA 9
$77.14
Below
EMA 21
$78.99
Below
EMA 50
$78.67
Below
EMA 200
$71.33
Above
Fundamental Analysis
Valuation
100
Growth
25
Profitability
50
Financial Health
68
Cash Flow
15
Valuation
P/E Ratio
-20.9×
P/B Ratio
-5.83×
PEG Ratio
-1.62
Dividend Yield
0.00%
52W High
$93.42
52W Low
$48.78
Quality & Growth
ROE
3512.1%
ROA
-7791.5%
Gross Margin
9314.1%
Operating Margin
-7855.5%
Revenue Growth YoY
—
Debt / Equity
-0.99
AI Fundamental Assessment
P/E ratio of -20.9 (inexpensive relative to a 15-40x range); Price-to-book of -5.8x; PEG ratio of -1.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 35.1%; Return on assets of -77.9%; Net margin of -100.6%; Gross margin of 93.1%; Current ratio of 1.23 (tight short-term liquidity); Debt-to-equity of -0.99; Free cash flow per share is negative (-3.02); Most recent quarter missed estimates by 31.1%; 4 consecutive earnings misses; EPS growth decelerating (+16.0% -> +7.1% QoQ); Analyst estimates rising over recent quarters
Get the Full BBIO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →